In support of the African decade of disabled persons | 1st January 199 - 31st of December 2009
Sixth Meeting of the mhGAP Forum Hosted by WHO in Geneva on 4-5 September 2014 Summary Report
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
LEAVING NO-ONE BEHIND | “A Journey to End NTDs – Elimination and Care” records what we have achieved over the last year and where we are now. It presents our plan of action for the coming years, bringing our ‘traditional’ NTD work together with ‘Disease Management Disability and Inclusio...n’ (DMDI), Community Based Inclusive Development (CBID) and Livelihoods. We care for those affected and we’re working to enhance community and government ownership through national
health system strengthening, community engagement and cross-sectoral action. Ultimately, we are working to free future generations from these menacing diseases, improving prevention and treatment, without forgetting those for whom prevention and treatment are too late because they already have a disability.
more
National-scale databases and reliability issue
Background report
The report offers an analysis of the broader challenges to securing humanitarian action and recommends areas for improvement. This study will contribute to improving the way humanitarians ‘do business’ in complex
security environments. Document also available in French, Arabic and Spanish.
Impact of EU policies on accessing protection. The report highlights the tragedy hundreds of thousands of people face when seeking protection in Europe. Women, men and children escaping war, repression and violation of human rights often turn to Europe in the hope of finding a safe haven. But many a...re instead confronted with bureaucratic hurdles, denial of protection and inconsistent reception standards across Europe.
more
Submitted to the US Agency for International Development by the
Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program.
This manual provides a framework to identify problems and design interventions to improve access to and use of medicines for children. It is a resource for ...both health policy makers and health system managers and presents a structured approach to the steps introduced in the framework in the context of child health.
more
The Burkina Faso Demographic and Health and Multiple Cluster Indicator Survey 2010 (DHS-MICS), or Enquête Démographique et de Santé et à Indicateurs Multiples du Burkina Faso 2010, was conducted by the Institut National de la Statistique et de la Démographie (INSD) of the Ministry of Economy a...nd Plan (MOEP) in collaboration with the Ministry of Health (MOH), with technical assistance from ICF International. Data for this nationally representative survey were collected from 14,424 households, and complete interviews were conducted with 17,087 women aged 15−49 and 7,307 men aged 15–59. The fieldwork took place from May 2010 to January 2011. The summary statistics presented below were taken from the 2010 Burkina Faso DHS-MICS (INSD and ICF International 2012), with exceptions as noted.
more
Hidden Burdens of Conflict
LESOTHO COPDAM BASELINE STUDY 2013
Regional Tuberculosis Program, Pan American Health Organization (PAHO/WHO)
The number of new Ebola infections in Sierra Leone is declining, despite the outbreak continuing to claim lives. New cases have dropped to around 9-12 per week, according to recent WHO figures. There were over 500 cases per week at the height of the crisis around late November 2014.
The impact on t...he lives of the thousands of people directly affected by the disease has been devastating. It has caused substantial suffering to many others, leaving the population very vulnerable.
more
The purpose of this Emergency Response Framework (ERF) is to clarify WHO’s roles and responsibilities in this regard and to provide a common approach for its work in emergencies. Ultimately, the ERF requires WHO to act with urgency and predictability to best serve and be accountable to populations... affected by emergencies.
more
The National Strategy for Natural Disaster, Prevention, Response and Mitigation to 2020, which outlines Vietnam’s main disaster risk management objectives and the National Target Program (NTP) form the overarching policy framework for disaster risk management and climate change adaption activities.... The CCFSC’s main mandate is to translate this strategy into action. Other decrees and laws are also complementary. The Government of Vietnam has prioritized disaster preparedness, recognizing that the most cost-effective measures to mitigate flood related disasters are often non-structural. These measures include flood mapping, river flood warning systems, television-based disaster information and warning systems, training at all government and grassroots levels on disaster preparedness, and reforestation of certain areas. Land use and development have also been addressed through government regulations.
more